source
- Latigo Biotherapeutics targets non-opioid pain market with $247 M IPOLatigo Biotherapeutics announced details of its planned initial public offering, aiming to raise roughly $247 million to advance its pipeline of non-opioid pain treatments. The company intends to…
- Early Alert: Intraosseous Needle Set Issue from Becton DickinsonBD is recalling certain BD Intraosseous Vascular Access System Needle Sets due to difficulty removing the obturator (stylet) following placement.